For our investors

Basilea reported significant revenue growth from marketed products and pipeline progress for full-year 2019

Read more

Our future growth and value generation is based on increasing revenues from our two marketed anti-infectives and positive data from our innovative pipeline

Investing in Basilea

  • Growing revenues: we continue to grow revenues from Cresemba and Zevtera, including launches in further markets
  • Building global brands: we strengthen and fully exploit the commercial potential from our marketed products. Our commercialization partnerships cover more than 100 countries
  • Solid cash position: allows us to explore opportunities to selectively expand our clinical oncology portfolio and pre-clinical pipeline through in-licensing and internal development
  • Growth potential: we are focused on advancing and expanding our R&D portfolio to create sustainable shareholder value

Current investor presentation

Events and presentations

May 19. 2020
UBS Virtual Global Healthcare Conference
Feb 18. 2020
Financial Results FY 2019 and publication of Annual Report 2019

Conference call: 4:00 p.m. CET

Webcast

For questions, please additionally dial-in via phone.

+41 (0) 58 310 5000     (Europe and RoW)
+1 (1) 866 291 4166       (USA)
+44 (0) 207 107 0613    (U.K.)

Replay:
The webcast, along with presentation will be available online shortly after the event and accessible for three months.

Jan 16. 2020
Bad Ragaz, Switzerland
Baader Swiss Equities Conference 2020

CSO presentation at 16:15 - 17:00

CSO  Presentation

Jan 13. 2020 - Jan 16. 2020
San Francisco, California , United States
38th Annual J.P. Morgan Healthcare Conference
Nov 21. 2019
London, United Kingdom
Jefferies Global Healthcare Conference

 

Archive

Annual General Meeting

Apr 08. 2020, 14:00 CEST
Congress Center of the Messe Basel in Basel, Switzerland
2020 Annual General Meeting of Shareholders

Important Notice - Coronavirus
Pursuant to Art. 6a of the COVID-19 Ordinance 2 issued by the Swiss Federal Council, voting at the AGM of Basilea Pharmaceutica Ltd. on April 8, 2020, will exclusively be by the Independent Proxy in accordance with instructions by shareholders. The participation of shareholders on site is neither possible nor permitted by the Federal Council's COVID-19 Ordinance 2.

Together with the AGM invitation, registered shareholders will receive documents with instructions guidance on how to issue the electronic or written proxy and voting instructions to the Independent Proxy.

Wichtige Mitteilung - Coronavirus
Gemäss Art. 6a der Verordnung 2 über Massnahmen zur Bekämpfung des Coronavirus des Bundesrats (COVID-19-Verordnung 2) wird die Stimmabgabe bei der am 8. April 2020 stattfindenden Generalversammlung der Basilea Pharmaceutica AG ausschliesslich über die unabhängige Stimmrechtsvertreterin in Übereinstimmung mit den entsprechenden Weisungen der Aktionäre erfolgen. Eine physische Teilnahme von Aktionären ist entsprechend der COVID-19-Verordnung 2 weder möglich noch erlaubt.

Registrierte Aktionäre erhalten mit den GV-Unterlagen eine Anleitung zur elektronischen bzw. schriftlichen Erteilung der Vollmacht und von Weisungen betreffend Ausübung des Stimmrechts an die unabhängige Stimmrechtsvertreterin.

 

Archive

Analyst coverage

The analysts listed on this page have published reports or commentary on Basilea; there may be other analysts who have published reports or commentary that are not referenced here.  Please note that any opinions, estimates or forecasts regarding Basilea's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Basilea or its management.  Basilea does not by its reference on this website imply any endorsement of or concurrence with such information, conclusions or recommendations.

FIRM ANALYST
Baader Helvea Bank Bruno Bulic
Bryan Garnier & Co. Victor Floc’h
Cantor Fitzgerald (U.K.) Brian White
Cantor Fitzgerald (U.S.) Louise Chen
Edison Susie Jana
goetzpartners securities Limited Chris Redhead
H. C. Wainwright & Co. Raghuram Selvaraju
Kepler Cheuvreux Arsene Guekam
LifeSci Capital David Sherman
Mirabaud Securities Limited Olav Zilian
Research Partners AG Paul Verbraeken
valuationLAB AG Bob Pooler

 

Share information

Corporate Governance

Articles of Association

Articles of Association
Statuten

Archive

Organisational Regulation

Organisational Regulation

Archive

Long-term incentive plan

Basilea has implemented a long-term incentive plan in the form of stock options, which vest after 3 and 4 years. The purpose of the Basilea stock option program is to provide Management Committee members and certain key employees with an opportunity to obtain stock options (or alternatively, stock appreciation rights), thus providing an incentive for participants to contribute to the mid and long-term success of the Company. The program is therefore aligned with shareholders’ interest to enhance shareholder value and also increases the ability of the Company to attract and retain individuals with exceptional skills. The plan has been amended to allow for gross and net settlement of stock options, which will be applied by the Company to ensure that the maximum potential dilution related to all granted options will stay below 10% of the share capital on a fully diluted basis.

Significant shareholders

SIX Website